Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

26 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Coagulation Factor IX Recombinant Articles

Takeda loses distribution of 13 Pfizer products in Japan

19 June 2012

Biovitrum's earnings flat on expenses

3 March 2008

Biovitrum's 2nd-qtr 2007 income soars 33%

10 September 2007

EMEA OKs BeneFix modifications

3 September 2007

Biovitrum enters Nordic BeneFIX co-promo deal

13 August 2007

BeneFIX rights revert to Wyeth after end of Baxter accord

9 July 2007

FDA approves ammendments to Wyeth's BeneFIX

2 April 2007

EMEA Committee for Orphan Medicinal Products holds inaugural meeting

3 May 2000

European launch of BeneFIX

2 February 1999

Major US pharma companies post strong rise in sales for full year 1998

27 January 1999

Healthy Third-Quarter Growth For US Drug Majors

22 October 1998

American Home Pharma Sales Up 7% For 2nd Qtr

22 July 1998

1997: Another Good Year For New Chemical Entities

6 January 1998

GI's Benefix Approved By EMEA

9 October 1997

Euro Union CPMP September Meeting

8 October 1997

Genetics Institute's Factor IX Approved In 1st Market

17 February 1997

Panel Recommends BeneFix For Approval

23 December 1996

BeneFix Up Against FDA Panel

2 December 1996

Showing 1-18 of 18 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS